Hola,
¿eres nuevo aquí?

Registrate y conecta tu empresa con financiación pública, partners y proyectos.

OncoNanoR

Financiado

Engineering the immunosuppressive microenvironment in mesothelioma with targeted...

Engineering the immunosuppressive microenvironment in mesothelioma with targeted LipidNanoParticles encapsulating self-amplifying RNA Malignant pleural mesothelioma (MPM) is a highly aggressive disease, where chemotherapy remains the standard of care, enabling an overall survival (OS) of 12 months. Anti-PD-1-based immunotherapy has not improved the patient's OS,... ver más

30/06/2025

UNIVERSIDADE DE CO...

216K€

Presupuesto del proyecto: 216K€

Líder del proyecto

UNIVERSIDADE DE COIMBRA No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Ver 2 Participantes

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2022-09-19

Línea de financiación objetivo El proyecto se financió a través de la siguiente ayuda:

HORIZON-WIDERA-2022-TALENTS-02-01: Fostering balanced brain circulation – ERA Fellowships

I+D

Cerrada hace 3 años

0% 100% 100%

2 Participantes

UNIVERSIDADE DE COIMBRA

215.77K€ | Lider

BLUEPHARMA

N.D. | Participante

Proyectos interesantes

NanoImmunoRT Synergizing enhanced radiotherapy with tumor-associated macr... 125K€ Cerrado

PCIN-2017-017 NANO-IMMUNOTHERAPY: INTRACELLULAR TARGETING OF CANCER CELLS... 100K€ Cerrado

MAGNOSTICS Biomimetic MAGnetic nanoparticles with homotypic targeting f... 173K€ Cerrado

PCIN-2017-129 NANO-INMUNOTERAPIA: TARGETING INTRACELULAR DE CELULAS TUMORA... 150K€ Cerrado

TheranoXome Engineered Exosomes for Stimuli-responsive Image-guided Drug... 181K€ Cerrado

PID2020-119368RB-I00 NANO-INMUNOTERAPIAS COMBINADAS BASADAS EN SIRNA APLICADAS... 295K€ Cerrado

Últimas noticias

29-11-2024: IDAE En las últimas 48 horas el Organismo IDAE ha otorgado 4 concesiones

29-11-2024: ECE En las últimas 48 horas el Organismo ECE ha otorgado 2 concesiones

29-11-2024: CMVAMADRID En las últimas 48 horas el Organismo CMVAMADRID ha otorgado 37 concesiones

Duración del proyecto: 33 meses Fecha Inicio: 2022-09-19
Fecha Fin: 2025-06-30

Líder del proyecto

UNIVERSIDADE DE COIMBRA

TRL 4-5

Presupuesto del proyecto 216K€

Descripción del proyecto Malignant pleural mesothelioma (MPM) is a highly aggressive disease, where chemotherapy remains the standard of care, enabling an overall survival (OS) of 12 months. Anti-PD-1-based immunotherapy has not improved the patient's OS, while providing only a response rate of 21%, owing to the immunosuppressive tumor microenvironment. The originality of this proposal relies on engineering a novel form of immunotherapy for the treatment of MPM, through activating the innate and adaptive tumor microenvironment, upon one single intravenous injection of self-amplifying RNA, intracellularly delivered by a targeted LipidNanoparticle, which has recently proven to successful target small drugs to orthotopic MPM. This proposal challenges a major dogma in onconanomedicine – targeting nucleic acids to extra-hepatic tumors - where I will have the guidance of Prof. Moreira from CNC, UC, who holds more than 25 years of experience in the field of targeted delivery to solid tumors, being a successful entrepreneur. Supervision will be complemented with the guidance of an immunologist (APaiva), clinical pathologist (ACarmo), expert on physical-chemistry of colloids (BSilva) and drug development (Sérgio Simões, supervisor at Bluepharma Pharmaceutical Industry). This Marie Sklodowska-Curie European Fellowship, in line with Europe Mission on Cancer, is a life time opportunity to gain a number of different transferable skills, mentoring and leadership, networking and knowledge dissemination, exploitation and communication. These will enable me to become a highly qualified researcher, able to generate and integrate differentiated and interdisciplinary knowledge, and with know-how on how to translate it towards the market and the patients. As such, a wide avenue of opportunities will be open to further pursue a career either in Academia as Principal Investigator/Group Leader or Senior Scientist in the R&D department of a company dedicated to cancer immunotherapies and/or complexes injectables.

Conecta tu I+D

Entra hoy

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores